Home Office consults on medicinal use of cannabis

Home Office consults on medicinal use of cannabis

June 22 2018 A review into the scheduling of cannabis for medicinal purposes will look for...

Measles outbreaks prompt reminder about MMR vaccination ahead of summer holidays

Measles outbreaks prompt reminder about MMR vaccination ahead of summer holidays

June 22 2018 Young people should ensure they have had both doses of the MMR vaccine, especially...

Smoking levels remain unchanged in Wales at 19%

Smoking levels remain unchanged in Wales at 19%

June 22 2018 A downward trend in the proportion of adults smoking has stalled at 19%, the annual...

GP services get 86% satisfaction rating in Wales

GP services get 86% satisfaction rating in Wales

June 20 2018 The percentage of people reporting they were satisfied with their GP services in...

NICE guideline says people with dementia should be involved in discussions about their care

NICE guideline says people with dementia should be involved in discussions about their care

June 20 2018 An updated NICE guideline has recommended that people with dementia should be...

  • Home Office consults on medicinal use of cannabis

    Home Office consults on medicinal use of cannabis

    Friday, 22 June 2018 16:15
  • Measles outbreaks prompt reminder about MMR vaccination ahead of summer holidays

    Measles outbreaks prompt reminder about MMR vaccination ahead of summer holidays

    Friday, 22 June 2018 15:46
  • Smoking levels remain unchanged in Wales at 19%

    Smoking levels remain unchanged in Wales at 19%

    Friday, 22 June 2018 15:40
  • GP services get 86% satisfaction rating in Wales

    GP services get 86% satisfaction rating in Wales

    Wednesday, 20 June 2018 18:50
  • NICE guideline says people with dementia should be involved in discussions about their care

    NICE guideline says people with dementia should be involved in discussions about their care

    Wednesday, 20 June 2018 18:47

a alert imageJanuary 10 2018

The medicines regulator has highlighted the different strengths of co-dydramol in its latest Drug Safety Update. 

For many years co-dydramol has been available at a fixed ratio of 1:50, combining dihydrocodeine 10mg and paracetamol 500mg. However, the MHRA’s latest DSU is advising that new strengths containing proportionately greater amounts of dihydrocodeine – co-dydramol 20/500 mg and co-dydramol 30/500 mg tablets – are becoming available.

Health professionals should take care to ensure the intended strength is clearly prescribed and the correct strength is dispensed. If the prescribed strength is unclear, the person dispensing should contact the prescriber for clarification, says the MHRA. It is also asking that health professionals “report suspected adverse drug reactions with opioids, including any harm from medication error, via the Yellow Card Scheme.”

The DSU newsletter of January 6 also asks health professionals to ask if a patient has been using herbal medicines when reporting any suspected adverse drug reaction. If herbal medicines or traditional Chinese medicines have been used, this information should be included on the Yellow Card scheme report.

Ideally, information about a herbal product should include the brand name, the list of ingredients, a copy of the package labelling if available, and any manufacturer details. Patients should also be advised to check for the Traditional Herbal Registration Certification Mark.

Another medicine included in the DSU newsletter is daclizumab (daclizumab beta), which is “now restricted to adults with relapsing multiple sclerosis who have had an inadequate response to at least two other disease-modifying therapies (DMTs) and for whom other DMTs are contraindicated or unsuitable.”

The MHRA is advising that patients with pre-existing hepatic disease or hepatic impairment should not use daclizumab. Before initiating treatment, patients should also be screened for hepatitis B and C viral infections. Treatment should also be closely monitored to check for any developing liver problems.

Initiation is not recommended in certain other circumstances: with raised aminotransferase (ALT) or aspartate aminotransferase (AST) levels or in those with autoimmune conditions other than multiple sclerosis. Caution should also be taken in prescribing daclizumab “in patients receiving other medication that may be hepatotoxic, including over-the-counter products and herbal medicines.”

Links:
MHRA Drug Safety Update: monthly PDF newsletters        
MHRA Drug Safety Update: monthly PDF newsletter. January 6 2018. 11;6.                 
Co-dydramol DSU             
Herbal medicines DSU    
Daclizumab DSU                

Professional News

June 22 2018 A review into the scheduling of cannabis for medicinal purposes will look for “significant medical and therapeutic benefits” before a decision is made.
June 6 2018 The Royal College of General Practitioners has called for visa regulations to be reviewed to allow more doctors to work as GPs in the NHS. Home Secretary Sajit Javid announced on Sunday...